Quick links
Government sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 

Lebanon Substitution Drug List - First edition 2015 (Revised)
 
     

According to the Law No. 91 issued on 2010 related to the Pharmacist substitution right, the Ministry of Public Health conceived the Substitution Drug list. It is presented as a scientific, objective, reliable, accurate and accessible listing. This list is a helpful tool for Pharmacists and Health professionals and an information tool for patients as well.

 

The Substitution Drug List was compiled by a team of Pharmacists and Physicians from the Ministry of Public Health. It was inspired by the French Repertory of Generic Groups and the Lebanese National Drug Index (LNDI) which is the reference Guide for medicines in Lebanon.

The substitution could be done between an innovator product and a generic, based on the Ministry of Public Health Substitution list, providing that the product delivered is cheaper and has obtained the patient’s consent.

 

This Substitution Drug List, lists drugs, dosage forms, package sizes, drug strengths and other information registered at the Ministry of Public Health. It is divided into sections based on the Anatomical Therapeutic Chemical (ATC) classification system. The Innovator product is listed before the Generic products.

Information is shown in a convenient format with trade information in italics:
ATCcode Trade Name & Strength B=Brand
 G=Generic
Route Form Container Presentation Code MOPH Registration Number at MOPH Active Ingredients with their respective dosage Agent importing product Manufacturer Country of Origin Responsible Party Country of Responsible Party


Each medication listing contains the following information:

ATC classification and code.
Trade name and strength of the formulation as registered at the Ministry of Public Health (MOH)
Generic (G) or Brand product (B)
Composition of the marketed form with the corresponding dosage of each active ingredient.
Form &presentation.
The local importer (agent), manufacturer and identified country of origin.
The Responsible Party and identified country.
The Ministry of Public Health database serial number (Code MOH) and legal registration document number (MOH reg)
 

The Substitution Drug List can be accessed from the official website of the Ministry of Public Health: www.moph.gov.lb

The Substitution Drug List welcomes comments from healthcare professionals. Please send comments to: mphealth@cyberia.net.lb

 

Walid Ammar MD, Ph.D

Director General

Ministry of Public Health

   
 

Lebanon Substitution Drug List - First Edition 2015 (Revised)

 
ATC brand_name B/G Ingredients Dosage Form Price
S01GX09 OLOHISTINE G Olopatadine (HCl) - 0.1% 0.1% Solution 344,024 L.L
S01GX09 OLOPAT G Olopatadine (HCl) - 0.1% 0.1% Drops solution 344,024 L.L
S01GX09 OLOPAT UD G Olopatadine (HCl) - 0.1% 0.1% Drops solution 1,523,917 L.L
S01HA02 ANESTOCIL B Oxybuprocaine HCl (Benoxinate HCl) - 0.4% 0.4% Drops solution 442,124 L.L
S01JA01 FLUORESCEIN SODIUM USP IV G Fluorescein sodium - 10% 10% Injectable solution 1,198,595 L.L
S01JA01 FLUORESCEIN SODIUM USP IV G Fluorescein sodium - 10% 10% Injectable solution 10,787,353 L.L
S01LA04 LUCENTIS BioTech Ranibizumab - 10mg/ml 10mg/ml Injectable solution L.L
S01LA04 LUCENTIS BioTech Ranibizumab - 10mg/ml 10mg/ml Injectable solution 51,255,093 L.L
S01LA05 EYLEA BioTech Aflibercept - 40mg/ml 40mg/ml Injectable solution L.L
S01LA05 EYLEA BioTech Aflibercept - 40mg/ml 40mg/ml Injectable solution 65,161,855 L.L
S01LA05 EYLEA BioTech Aflibercept - 8mg/0.07ml 114.3mg/ml Injectable solution 78,332,038 L.L
S01LA06 BEOVU BioTech Brolucizumab - 120mg/ml 120mg/ml Injectable solution L.L
S01LA06 BEOVU BioTech Brolucizumab - 120mg/ml 120mg/ml Injectable solution 42,752,178 L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution 54,991,170 L.L
S01XA18 RESTASIS B Ciclosporin - 0.5mg/ml 0.05% Emulsion 4,100,063 L.L
S01XA18 RESTASIS B Ciclosporin - 0.5mg/ml 0.05% Emulsion 4,100,063 L.L
S01XA18 DRYFREE G Ciclosporin - 0.05% 0.05% Drops 2,257,655 L.L
S01XA18 ESTAPORIN G Ciclosporin - 0.05% 0.05% Emulsion 2,815,798 L.L
S01XA20 LUBRI-TEARS G Carmellose sodium - 2mg Drops solution 792,867 L.L
S02AA15 CETRAXAL OTICO G Ciprofloxacine (HCl) - 3mg/ml 3mg/ml Drops 821,088 L.L
S02AA15 SEPTOCIPRO OTICO B Ciprofloxacine (HCl) - 1mg/0.5ml 1mg/0.5ml Solution 473,033 L.L
S02AA16 OFLOMED G Ofloxacin - 3mg/ml 3mg/ml Drops solution 317,403 L.L
S02AA30 TYOTOCIN B Hexylresorcinol - 0.1%, Antipyrine - 5%, Benzocaine - 1.25%, Tyrothricin - 0.05% Drops solution 409,552 L.L
S02AA30 OTOCOL G Chloramphenicol - 50mg/ml, Benzocaine - 50mg/ml Drops 163,949 L.L
S02CA02 VIOCORTENE B Clioquinol - 10mg/ml, Flumetasone pivalate - 0.2mg/ml Drops 568,253 L.L
S02CA05 CETRAXAL PLUS G Ciprofloxacine HCl monohydrate - 3mg/ml, Fluocinolone acetonide - 0.25mg/ml Drops solution 795,555 L.L
S02CA06 POLYDEXA G Dexamethasone sodium metasulfobenzoate - 1.000.000IU/100ml, Polymyxin B sulfate - 100mg/100ml, Neomycin sulfate - 650.000IU/100ml Drops solution 208,296 L.L
S02CA06 AURICULARUM G Dexamethasone (sodium phosphate) - 10mg, Nystatin - 1,000,000IU, Oxytetracycline HCl - 90,000IU, Polymyxin B sulfate - 100,000IU Powder for suspension + solvent 755,239 L.L
S02CA07 PAROTICIN G Fludrocortisone acetate - 1mg/ml, Polymyxin B (sulfate) - 10.000IU/ml, Lidocaine - 50mg/ml Drops solution 319,835 L.L
Sitemap
© Copyrights reserved to Ministry of Public Health 2026